Brief: PCI Biotech: Pre-clinical research collaboration with large pharma co extended
26/05/2016 07:09
May 26 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* Says pre-clinical research collaboration agreement with top-10 large pharma company
extended until the end of 2016
* Says aim of research collaboration is to evaluate synergistic effects of both parties'
technology platforms, to determine whether PCI Biotech's fimaNAc technology has potential to
enhance therapeutic effect of partner's nucleic acid therapeutic compounds
Source text for Eikon: ID:nHUG47bp50
Further company coverage: PCIB.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process